We develop "Solubility Chaperones" to physically rescue p53-R175H mutants and reactivate tumor suppression in high-grade malignancies.
A unified pharmacological approach for structural stabilization and dual-target inhibition.
Lead Program (ATX-101): Targets R175H Mutants. Functions as a solubility chaperone, stabilizing the mutant core to prevent toxic aggregation while enabling immune clearance.
Discovery (ATX-102): Targets WT p53 Tumors. Exploits the hypoxic stress of the tumor microenvironment to dock onto stabilized p53 and block the HIF-1α angiogenesis pathway.
Rare Disease (ATX-103): Targets MEN-1 Syndrome. Acts as a high-affinity steric shield on the p300 KIX domain, blocking the oncogenic JunD driver in neuroendocrine tumors.